Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

1. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. (Abstract)

Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy characterised by multiple types of frequent, disabling seizures. Fenfluramine has been reported to have antiseizure activity in observational studies of photosensitive epilepsy and Dravet syndrome. The aim of the present study was to assess the efficacy and safety of fenfluramine (...) in patients with Dravet syndrome.In this randomised, double-blind, placebo-controlled clinical trial, we enrolled children and young adults with Dravet syndrome. After a 6-week observation period to establish baseline monthly convulsive seizure frequency (MCSF; convulsive seizures were defined as hemiclonic, tonic, clonic, tonic-atonic, generalised tonic-clonic, and focal with clearly observable motor signs), patients were randomly assigned through an interactive web response system in a 1:1:1 ratio

2020 Lancet

2. Seizures-Child

of classifications of seizures: a preliminary study with 28 participants and 48 seizures. Epilepsy Behav. 2005;6(4):607-612. 5. Pellock JM. The classification of childhood seizures and epilepsy syndromes. Neurol Clin. 1990;8(3):619- 632. 6. Scheuer ML, Pedley TA. The evaluation and treatment of seizures. N Engl J Med. 1990;323(21):1468-1474. 7. Engel J, Jr. Report of the ILAE classification core group. Epilepsia. 2006;47(9):1558-1568. 8. Panayiotopoulos CP. Neonatal Epileptic Seizures and Syndromes. Available (...) Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-472. 3. Weitemeyer L, Kellinghaus C, Weckesser M, et al. The prognostic value of [F]FDG-PET in nonrefractory partial epilepsy. Epilepsia. 2005;46(10):1654-1660. ACR Appropriateness Criteria ® 9 Seizures — Child 4. Baykan B, Ertas NK, Ertas M, Aktekin B, Saygi S, Gokyigit A. Comparison

2020 American College of Radiology

3. Cannabidiol (Epidyolex) - As adjunctive therapy of seizures associated with Lennox?Gastaut syndrome (LGS) in conjunction with clobazam, for patients 2 years of age and older.

estimated using a direct elicitation exercise, where 11 patients with epilepsy and 19 caregivers of patients with epilepsy were asked to value a series of vignettes through the perspective of a patient with Lennox-Gastaut Syndrome using a Visual Analogue Scale (VAS). Although not derived using a ‘choice-based’ approach, the company utilised mean estimates from this exercise in the base case (utilities ranged from 0.75 [‘seizure-free’] to 0.235 [= 3 seizure-free days with more than 110 seizures (...) providing tertiary epilepsy specialist care and when treatment with lamotrigine, rufinamide and topiramate has proved ineffective or not tolerated. 11 The Scottish Intercollegiate Guidelines Network (SIGN) issued publication number 148: diagnosis and management of epilepsy in adults in May 2015 and it was updated in 2018. This makes no specific recommendations on the treatment of Lennox-Gastaut syndrome, but notes that drop attacks in patients with Lennox-Gastaut syndrome may respond to rufinamide. 15

2020 Scottish Medicines Consortium

4. Cannabidiol (Epidyolex) - As adjunctive therapy of seizures associated with  Dravet syndrome (DS) in conjunction with clobazam, for patients 2 years of age and older.

with Dravet syndrome (70% to 80%) have abnormalities in the sodium channel a1 subunit gene (SCN1A). 2 6 Stiripentol 6 is the only other medicine specifically licensed for Dravet syndrome, although sodium valproate and clobazam, licensed for use in epilepsy, 2,7,8 are widely used in Dravet syndrome. Sodium valproate is often used to prevent initial recurrence of convulsive seizures, and benzodiazepines (for example, diazepam, midazolam, clonazepam, or clobazam) are frequently co- administered to limit (...) as follows: ADVICE: following a full submission considered under the orphan process cannabidiol (Epidyolex ® ) is accepted for use within NHSScotland. Indication under review: for use as adjunctive therapy of seizures associated with Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. In two phase III, placebo-controlled studies cannabidiol reduced convulsive seizure frequency in the clobazam-treated subgroup of children (aged 2 to 18 years) with Dravet syndrome

2020 Scottish Medicines Consortium

5. Cannabidiol (Epidyolex) in certain severe forms of childhood epilepsy: an option to consider, but liver function must be monitored

with antiepileptic treatment including at least clobazam. How do Prescrire's editors rate this treatment in this situation? Full text (3 pages) available for download by subscribers. Lennox-Gastaut syndrome and Dravet syndrome are severe forms of epilepsy that affect children and infants. Pharmacological treatment is based on combinations of antiepileptic drugs, sometimes including valproic acid and cloba­zam.These combinations frequently fail to fully prevent seizures. An oral solution of cannabidiol (...) , the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Cannabidiol (Epidyolex°) in certain severe forms of childhood epilepsy: an option to consider, but liver function must be monitored FEATURED REVIEW Cannabidiol (Epidyolex°) has been granted marketing authorisation in the European Union for patients aged 2 years and older with Lennox-Gastaut syndrome or Dravet syndrome, in combination

2020 Prescrire

6. Efficacy of Ketogenic Diet, Modified Atkins Diet, and Low Glycemic Index Therapy Diet Among Children With Drug-Resistant Epilepsy: A Randomized Clinical Trial

. doi: 10.1001/jamapediatrics.2020.2282. Online ahead of print. Efficacy of Ketogenic Diet, Modified Atkins Diet, and Low Glycemic Index Therapy Diet Among Children With Drug-Resistant Epilepsy: A Randomized Clinical Trial , , , , , , , , , , Affiliations Expand Affiliations 1 Center of Excellence & Advanced Research on Childhood Neurodevelopmental Disorders, Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. 2 Department of Pediatrics, All (...) Among Children With Drug-Resistant Epilepsy: A Randomized Clinical Trial Vishal Sondhi et al. JAMA Pediatr . 2020 . Show details Display options Display options Format JAMA Pediatr Actions . 2020 Aug 3;e202282. doi: 10.1001/jamapediatrics.2020.2282. Online ahead of print. Authors , , , , , , , , , , Affiliations 1 Center of Excellence & Advanced Research on Childhood Neurodevelopmental Disorders, Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi

2020 EvidenceUpdates

7. Deep brain stimulation for refractory epilepsy in adults

of 52 2 The condition, current treatments and The condition, current treatments and procedure procedure The condition The condition 2.1 Epilepsy is a neurological condition characterised by episodes of abnormal electrical activity in the brain which cause recurrent seizures. The seizures can be focal or generalised. Current treatments Current treatments 2.2 The main treatment for epilepsy is anti-epileptic drugs taken to prevent or reduce the occurrence of seizures. However, many people have drug (...) epilepsy. 1.5 Further research should describe patient selection and clearly define the target area of the brain. Outcomes should include reduction in seizure frequency and improvement in the epilepsy seizure outcome scale, quality of life, reduction in concomitant medication and hospital admissions. Deep brain stimulation for refractory epilepsy in adults (IPG678) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2020 National Institute for Health and Clinical Excellence - Interventional Procedures

8. Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial

of Biomedical and Neuromotor Sciences, University of Bologna, Italy. PMID: 32601123 DOI: Item in Clipboard Full-text links Cite Abstract Objective: To determine whether systematic screening for adverse effects of antiepileptic drugs (AEDs) reduces toxicity burden and improves health-related quality of life in patients with epilepsy. Methods: Consecutive patients with uncontrolled seizures aged ≥16 years and a high Adverse Event Profile (AEP) score were randomized to 2 groups and followed up for 18 months (...) MP, De Sarro G, Fattore C, Galimberti CA, Gatti G, La Neve A, Muscas G, Specchio LM, Striano S, Perucca E; SOPHIE Study Group. Luoni C, et al. Epilepsia. 2011 Dec;52(12):2181-91. doi: 10.1111/j.1528-1167.2011.03325.x. Epilepsia. 2011. PMID: 22136077 Clinical Trial. Micoulaud-Franchi JA, Bartolomei F, Duncan R, McGonigal A. Micoulaud-Franchi JA, et al. Epilepsy Behav. 2017 Oct;75:18-24. doi: 10.1016/j.yebeh.2017.07.016. Epub 2017 Aug 15. Epilepsy Behav. 2017. PMID: 28818810 LeBlanc EL, Patnode CD

2020 EvidenceUpdates

9. Vigabatrin add-on therapy for drug-resistant focal epilepsy. (Abstract)

) and nystagmus (RR 1.53, 99% CI 0.62 to 3.76; 2 studies; low-certainty evidence). Vigabatrin had little to no effect on cognitive outcomes or quality of life.Vigabatrin may significantly reduce seizure frequency in people with drug-resistant focal epilepsy. The results largely apply to adults and should not be extrapolated to children under 10 years old. Short-term follow-up of participants showed that some adverse effects were associated with its use. Analysis of longer-term observational studies elsewhere (...) Vigabatrin add-on therapy for drug-resistant focal epilepsy. This is an updated version of the original Cochrane Review published in 2008 and updated in 2013. Epilepsy is a common neurological condition which affects up to 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs. The majority of these people have focal epilepsy. Vigabatrin is an antiepileptic drug licensed for use in drug-resistant epilepsy.To assess the efficacy

2020 Cochrane

10. Zonisamide add-on therapy for focal epilepsy. (Abstract)

Zonisamide add-on therapy for focal epilepsy. The majority of people with epilepsy have a good prognosis, and their seizures can be well controlled with the use of a single antiepileptic agent, but up to 30% develop dug-resistant epilepsy, especially those with focal seizures. In this review, we summarised the evidence from randomised controlled trials (RCT) of zonisamide, used as an add-on treatment for focal epilepsy uncontrolled by one or more concomitant antiepileptic drug (...) studies.Randomised controlled trials, in which add-on zonisamide was compared with placebo or another antiepileptic drug in people with focal epilepsy, uncontrolled by one or more concomitant antiepileptic drugs.Two review authors independently selected trials for inclusion, extracted data, assessed for risk of bias using the Cochrane 'Risk of bias' tool, and assessed the certainty of the evidence, using the GRADE approach. The primary outcome was at least a 50% reduction in total seizure frequency

2020 Cochrane

11. Keeping people with epilepsy safe during the COVID-19 pandemic

, impaired immune function due to underlying conditions or drug treatment, and older age, particularly when associated with frailty. People with epilepsy may also have any of these conditions. Because autoimmune disorders are associated with an increased risk of epilepsy and are often treated with immunosuppressive therapies, this is a concern for some people with epilepsy. Individuals with tuberous sclerosis complex, which is often accompanied by epileptic seizures, may have reduced lung function (...) and may also be treated with immune therapy. For certain epilepsy syndromes such as Dravet syndrome, as well as for other epilepsies where seizures are triggered by fever or illness, there may be a risk of worsening in a person with fever due to COVID-19. To date, case reports of worsening have not come forward, which is reassuring. Children are less likely to have severe respiratory illnesses (0.9% 0–14 years in China, 1.5% affected were younger than 20 years in Italy ). c. Are there medications

2020 American Epilepsy Society

12. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures (Full text)

Actions Cite Share Permalink Copy Page navigation Neurology Actions . 2020 Jun 2;94(22):e2311-e2322. doi: 10.1212/WNL.0000000000009530. Epub 2020 May 14. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures , , , , , , , , , Affiliations Expand Affiliations 1 From the Neuroscience Institute (S.S.C), Banner-University Medical Center, University of Arizona, Phoenix; NYU Langone Comprehensive Epilepsy Center (J.A.F.), New York; NZOZ Vito-Med (J.K.), Gliwice (...) Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology

2020 EvidenceUpdates PubMed abstract

13. Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. (Abstract)

Lamotrigine add-on therapy for drug-resistant generalised tonic-clonic seizures. This is an update of the Cochrane Review first published in 2010; it includes one additional study. Primary generalised tonic-clonic seizures are a type of generalised seizure. Other types of seizures include: absence, myoclonic, and atonic seizures. Effective control of tonic-clonic seizures reduces the risk of injury and death, and improves quality of life. While most people achieve seizure control with one (...) antiepileptic drug, around 30% do not, and require a combination of antiepileptic drugs.To assess the effectiveness and tolerability of add-on lamotrigine for drug-resistant primary generalised tonic-clonic seizures.For the latest update, we searched these databases on 19 March 2019: Cochrane Register of Studies (CRS) Web, MEDLINE Ovid, and the WHO International Clinical Trials Registry Platform (ICTRP). The CRS includes records from the Cochrane Epilepsy Group Specialized Register, CENTRAL, Embase

2020 Cochrane

14. Ketogenic diets for drug-resistant epilepsy. (Abstract)

Ketogenic diets for drug-resistant epilepsy. Ketogenic diets (KDs) are high in fat and low in carbohydrates and have been suggested to reduce seizure frequency in people with epilepsy. Such diets may be beneficial for children with drug-resistant epilepsy. This is an update of a review first published in 2003, and last updated in 2018.To assess the effects of ketogenic diets for people with drug-resistant epilepsy.For this update, we searched the Cochrane Register of Studies (CRS Web (...) a similar effect on seizure control as the classical KD, but could be associated with fewer adverse effects. This assumption requires more investigation. For people who have drug-resistant epilepsy or who are unsuitable for surgical intervention, KDs remain a valid option. Further research is required, particularly for adults with drug-resistant epilepsy.Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2020 Cochrane

15. Gynecologic Management of Adolescents and Young Women With Seizure Disorders

with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older . General Contraceptive Considerations Adolescents with seizure disorders require ongoing education about potential adverse pregnancy outcomes and the most effective contraceptive options. Ideally, education should begin in early adolescence and continue throughout a patient’s reproductive lifespan because antiepileptic drugs, contraceptive needs, and desire for pregnancy may (...) 2011;52:199–211. Article Locations: Cummings LN, Giudice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia 1995;36:355–9. Article Locations: Tauboll E, Sveberg L, Svalheim S. Interactions between hormones and epilepsy. Seizure 2015;28:3–11. Article Locations: Morrell MJ, Hayes FJ, Sluss PM, Adams JM, Bhatt M, Ozkara C, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008;64:200–11. Article Locations: Joffe H, Cohen LS

2020 American College of Obstetricians and Gynecologists

16. Stiripentol add-on therapy for drug-resistant focal epilepsy. (Abstract)

Stiripentol add-on therapy for drug-resistant focal epilepsy. This is an updated version of the Cochrane Review first published in 2014, and last updated in 2018. For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is an antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as an adjunctive therapy with valproate and clobazam.To evaluate (...) , Embase, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (ICTRP). We contacted Biocodex (the manufacturer of stiripentol) and epilepsy experts to identify published, unpublished and ongoing trials.Randomised, controlled, add-on trials of stiripentol in people with drug-resistant focal epilepsy.Review authors independently selected trials for inclusion and extracted data. We investigated outcomes including 50% or greater reduction in seizure

2020 Cochrane

17. Covid-19: Epilepsy

are challenged by the new SARS-CoV-2 virus causing corona virus disease 2019 (COVID-19). The virus is causing mainly viral pneumonia and respiratory tract infection. In this statement, we will focus on the impact of COVID-19 on epilepsy. To our knowledge, no publication covering epilepsy, seizures or paroxysmal events has so far been published in relation to COVID-19. However, there are several general aspects to address: During the previous SARS epidemic, some people with epilepsy (PwE) stopped taking (...) their medicine due to isolation, or fear of contracting infection from hospitals, doctors’ offices, pharmacies or surgical procedures. This obviously leads to an increased risk for seizures and status epilepticus with all related complications including injuries, hospital admissions, and potentially sudden unexpected death in people with epilepsy (SUDEP). Hence, patient information is very important and should stress the importance of maintaining concordance with and supply of prescribed medication. COVID-19

2020 European Academy of Neurology

18. Managing Patients with Epilepsy during COVID-19 - Pharmacotherapy-related Recommendations

will wane over a few days. Nasal decongestant products should be avoided. In some places, herbal products that contain various constituents, such as Ma Huang (ephedra), have been used in treating COVID-19. These products should be avoided in patients with epilepsy as they may interact with ASM and could exacerbate seizures. Patients should always be asked about nonprescription medication and natural product use when taking a medication history. Possible Drugs for Treating COVID-19 Several different (...) Managing Patients with Epilepsy during COVID-19 - Pharmacotherapy-related Recommendations COVID-19 | Pharmacotherapy and Epilepsy | American Epilepsy Society Google Tag Manager | | | You are here » COVID-19 | Pharmacotherapy and Epilepsy COVID-19 | Pharmacotherapy and Epilepsy T his page was last updated April 17, 2020 Managing Patients with Epilepsy during COVID-19 Pharmacotherapy-related Recommendations Prepared by a Task Force of the AES Council on Clinical Activities: Timothy Welty, PharmD

2020 American Epilepsy Society

19. Antiepileptic drugs as prophylaxis for postcraniotomy seizures. (Abstract)

Antiepileptic drugs as prophylaxis for postcraniotomy seizures. This is an updated version of the Cochrane Review previously published in 2018. The incidence of seizures following supratentorial craniotomy for non-traumatic pathology has been estimated to be between 15% to 20%; however, the risk of experiencing a seizure appears to vary from 3% to 92% over a five-year period. Postoperative seizures can precipitate the development of epilepsy; seizures are most likely to occur within the first (...) month of cranial surgery. The use of antiepileptic drugs (AEDs) administered pre- or postoperatively to prevent seizures following cranial surgery has been investigated in a number of randomised controlled trials (RCTs).To determine the efficacy and safety of AEDs when used prophylactically in people undergoing craniotomy and to examine which AEDs are most effective.For the latest update we searched the following databases on 29 September 2019: Cochrane Epilepsy Group Specialized Register, CENTRAL

2020 Cochrane

20. Barriers and facilitators to implementation of epilepsy self-management programs: a systematic review using qualitative evidence synthesis methods. (Full text)

Barriers and facilitators to implementation of epilepsy self-management programs: a systematic review using qualitative evidence synthesis methods. Epilepsy affects nearly 50 million people worldwide. Self-management is critical for individuals with epilepsy in order to maintain optimal physical, cognitive, and emotional health. Implementing and adopting a self-management program requires considering many factors at the person, program, and systems levels. We conducted a systematic review (...) of qualitative and mixed-methods studies to identify facilitators and barriers that impact implementation and adoption of self-management programs for adults with epilepsy.We used established systematic review methodologies for qualitative and mixed-methods studies. We included studies addressing facilitators (i.e., factors that aided) or barriers (i.e., factors that impeded) to implementation and adoption of self-management interventions for adults with epilepsy. We conducted a narrative thematic synthesis

2020 Systematic reviews PubMed abstract